Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone marrow transplants--quo vadis?].

B Speck, A Gratwohl, C Nissen

    Schweizerische Medizinische Wochenschrift
    |July 23, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

    Leukemia·2017
    Same author

    Latin America: the next region for haematopoietic transplant progress.

    Bone marrow transplantation·2017
    Same author

    Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

    Leukemia·2017
    Same author

    Latin America: the next region for haematopoietic transplant progress.

    Bone marrow transplantation·2017
    Same author

    The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

    Bone marrow transplantation·2016
    Same author

    Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

    Leukemia & lymphoma·2016

    Bone marrow transplantation (BMT) has improved outcomes for leukemia and aplastic anemia. Advances like cyclosporin-A reduce graft-versus-host disease, though donor availability and relapse remain challenges.

    Area of Science:

    • Hematology
    • Immunology
    • Transplantation Medicine

    Context:

    • Bone marrow transplantation (BMT) has significantly advanced treatment for hematologic malignancies and bone marrow failure syndromes.
    • Graft-versus-host disease (GvHD) and graft failure are major complications, alongside disease relapse in leukemia.
    • Limited availability of histocompatible donors presents a significant challenge for BMT accessibility.

    Purpose:

    • To review the current status and challenges of bone marrow transplantation (BMT) in leukemia and aplastic anemia.
    • To highlight advancements in immunosuppression and alternative donor sources.
    • To discuss the evolving role of BMT in modern medicine.

    Summary:

    • Early BMT has improved outcomes in leukemia, with reduced relapse and transplant-related mortality.

    Related Experiment Videos

  • Antilymphocyte globulin (ALG) provides an alternative to BMT for aplastic anemia patients lacking a matched donor.
  • Cyclosporin-A (CyA) effectively prevents severe GvHD, with potential for combination therapies.
  • Expanding donor pools (unrelated, HLA-semicompatible) and alternative stem cell sources are crucial for future BMT success.
  • While challenges like donor availability and relapse persist, BMT remains a vital therapeutic option.

    • Impact:

    • Improved survival rates for patients with leukemia and aplastic anemia.
    • Reduced incidence of severe graft-versus-host disease through effective immunosuppression.
    • Increased BMT feasibility for patients without matched family donors.
    • Established BMT as a cornerstone therapy in hematology and oncology.
    • Identified key areas for future research and development in transplantation medicine.